類風濕性關節炎市場：競爭環境與臨床階段分析 是由出版商Arrowhead Publishers在2009年05月所出版的。
這份英文市場調查報告書包含125 Pages 價格從美金1495起跳。
本研究報告分析全球類風濕性關節炎治療藥物市場，並分析比較已上市，以及尚在研究開發階段之主要藥物概況，將其整理如下。
第1章 研究執行摘要
第2章 類風濕性關節炎：科学的背景
- 疾病概要
- 病因
- 免疫反應
- 症状
- 診斷
- 風險因素
- 主要檢驗項目
- 預後診斷
第3章 類風濕性關節炎之經濟影響與人口統計
第4章 類風濕性關節炎現今治療法
- 非類固醇消炎藥物
- 皮質類固醇
- 緩和疾病之抗風濕藥物
- 生物反應調節藥物
- 外科治療
- 其他
第5章 影響全球類風濕性關節炎市場之問題與動向
- 生物反應調節療法之市場持續力量
- DMARD與BRM
- 高漲的生物製藥成本
- 美國醫療改革之影響
- 類風濕性關節炎治療藥物及全球償付問題
第6章 全球類風濕性關節炎治療藥物市場
第7章 類風濕性關節炎之研究開發途徑
- 未滿足之需求
- 類風濕性關節炎治療藥物之研究開發動向
- 第3相藥物製品
- 第2相藥物製品
第8章 類風濕性關節炎治療藥物市場的經濟展望
圖表
Abstract
Rheumatoid arthritis, a systemic disease characterized by inflammation of the
membrane lining the joint, is one of the most common forms of arthritis. Up to
50 percent of all rheumatoid arthritis patients enter early retirement within
five years of diagnosis, which means that the indirect costs associated with
this disease can be very high. While the prevalence of rheumatoid arthritis
has decreased in recent years, partly due to stricter diagnosing criteria as
well as other unknown factors, the higher uptake of rheumatoid arthritis
therapies continues to represent a major commercial opportunity for
pharmaceutical companies involved in the research and development of novel
therapies for the disease.
The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage
Analysis is an analytically-based overview of the current state of the global
market for rheumatoid arthritis therapies, with a focus on the specific class
of drugs, known as the biological response modifiers (BRMs). Biological
response modifiers have revolutionized the treatment of rheumatoid arthritis,
although their high cost (of up to $16,000 per patient per annum), has been a
major point of contention for both Medicare reimbursement as well as private
insurers. Consequently, an increasing amount of attention has been devoted to
research into their cost-effectiveness as compared to other therapies, as well
as one another. This report compares and contrasts the key rheumatoid
arthritis therapies on the market as well as in research and development.
The report also offers a comprehensive overview of therapeutics currently in
clinical development, with a view to assessing their impact on the future
performance of leading rheumatoid arthritis drugs. As a class, biological
response modifiers will, without a doubt, continue to make a major impact on
the rheumatoid arthritis market. However, the leading drugs within this class
are facing challenging times ahead, with a number of new products already
reaching registration phases, led by Centocor/Schering-Plough' s Simponi and
Celltech/UCB' s Cimzia.
The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage
Analysis provides sales figures for major rheumatoid therapies, dating back to
2003, as well as sales forecasts through 2013. Apart from patent expirations
facing current biological response modifiers and new product launches, which
will increase price competition, there are a few other factors expected to
slow down growth in this market during the next five years. For example,
recent developments in the United Kingdom (UK) suggest that cost-containment
may limit the use of expensive biologics if the first course of treatment
fails. Similarly, a more intense scrutiny of adverse drug reactions may also
limit this class' s reach in the market, although such issues will continue to
be the driving force behind research into safer and more convenient methods of
administration.
What Questions Does this Report Answer?
- What is the current competitive landscape of the rheumatoid arthritis
market look like?
- What is the current status of emerging products with significant growth
potential?
- What are the major clinical, economic and demographic drivers of the
rheumatoid arthritis market?
- What does the future competitive landscape of the rheumatoid arthritis
market look like?
- How will the issue of cost-effectiveness impact the future of the
rheumatoid arthritis market?
- Will developmental-stage therapies be judged to a greater degree on the
basis of cost-effectiveness in the near future?
Unique Features of this Report
- Clinically-based evaluation of leading rheumatoid arthritis therapies on
the market and in development
- Identification of trends and issues that will have a significant impact on
drug sales within the rheumatoid arthritis market.
- Market share metrics for key therapies as well as the overall rheumatoid
arthritis market, by country/region
- Measurement of key clinical trials as a means of determining future
success of product candidates in the market.
- SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of
leading rheumatoid arthritis therapies
- Forecasts of financial growth of this sector as a whole, as well as
forecasts of revenue for key products in the field (all forecasts through
2013).
Highlights of this Report
- Discussion of rheumatoid arthritis therapies and their use in a number of
key global markets.
- Discussion of the future of key rheumatoid arthritis therapies in light of
scientific and medical developments.
- Focused analysis of various key R&D-stage therapies for rheumatoid
arthritis.
- Identification of key trends within the rheumatoid arthritis market.
Reasons to Buy this Report
- The report provides an analysis-focused guide to the global market for
rheumatoid arthritis therapeutics.
- The report provides important background about the disease, its etiology,
patient population and financial and economic impact of the condition.
- The report provides a comparison of key rheumatoid arthritis therapies in
a number of major markets.
- The report provides a scenario for the future use of leading rheumatoid
arthritis therapies through the discussion of drivers and constraints.
- The report identifies key companies involved in the research and
development of rheumatoid arthritis therapies.
Table of Contents
1 EXECUTIVE SUMMARY
- 1.1 Scope and Methodology
- 1.2 Rheumatoid Arthritis: Disease Background, Impact and Treatment
- 1.3 Market Growth
- 1.4 Research and Development (R&D) Trends
2 RHEUMATOID ARTHRITIS: SCIENTIFIC BACKGROUND
- 2.1 Disease Overview
- 2.2 Etiology of Rheumatoid Arthritis
- 2.3 The Immune Response
- 2.3.1 Cytokines
- 2.3.2 Helper T-Cells and RA
- 2.3.3 Leukocytes
- 2.4 Symptoms
- 2.5 Diagnosis
- 2.5.1 Diagnostic Criteria
- 2.6 Risk Factors
- 2.6.1 Genetic Factors
- 2.6.2 Stress Hormones
- 2.6.3 Gender
- 2.6.4 Age
- 2.6.5 Family History
- 2.6.6 Ethnic Background
- 2.7 Key Clinical Trial Endpoints
- 2.7.1 American College of Rheumatology (ACR) Disease Activity Measures
- 2.7.2 EULAR (European League Against Rheumatism) Response Criteria
- 2.7.3 Erythrocyte Sedimentation Rate (ESR)
- 2.7.4 C-Reactive Proteins (CRP)
- 2.8 Prognosis
3 THE FINANCIAL AND DEMOGRAPHIC IMPACT OF RHEUMATOID ARTHRITIS
- 3.1 The Prevalence and Incidence of Rheumatoid Arthritis
- 3.2 The Financial Impact of Rheumatoid Arthritis
4 CURRENT TREATMENT OPTIONS FOR RHEUMATOID ARTHRITIS
- 4.1 NSAIDs
- 4.2 Corticosteroids
- 4.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
- 4.4 Biological Response Modifiers (BRMs)
- 4.4.1 Key Biological Response Modifiers
- 4.5 Surgical Treatments
- 4.5.1 Osteotomy
- 4.5.2 Synovectomy
- 4.5.3 Arthroscopic Surgery
- 4.5.4 Arthroplasty
- 4.5.5 Arthrodesis
- 4.6 Other Existing Treatments
5 ISSUES AND TRENDS IMPACTING THE GLOBAL MARKET FOR RA THERAPIES
- 5.1 Biological Response Modifiers as a Continued Market Force
- 5.2 DMARDs vs BRMs
- 5.3 The High Cost of RA Biologics
- 5.4 Medicare Reform in the US: Impact on RA Market
- 5.5 RA Therapies and Global Reimbursement Issues
6 THE GLOBAL MARKET FOR RA THERAPIES
- 6.1 Commercial Market Size
- 6.1.1 US Revenues
- 6.1.2 Non-US Revenues
- 6.2 Key Products Driving Growth
- 6.2.1 Enbrel: Market Position and Revenues
- 6.2.2 Remicade: Market Position and Revenues
- 6.2.3 Humira: Market Position and Revenues
- 6.2.4 Orencia: Market Position and Revenues
- 6.2.5 Rituxan: Market Position and Revenues
- 6.2.6 Kineret: Market Position and Revenues
- 6.3 Market Share
- 6.3.1 By Product
- 6.3.2 By Country/Region
7 THE R&D PIPELINE FOR RA THERAPIES
- 7.1 Unmet Need
- 7.2 R&D Trends in RA Therapy
- 7.2.1 Products Nearing Commercialization
- 7.2.2 Future Directions
- 7.3 R&D Trends in RA Therapy
- 7.3.1 Cimzia (CDP-870)
- 7.3.2 Actemra
- 7.3.3 Simponi
- 7.4 Selected Phase III Products in Development
- 7.4.1 Arzerra (HuMax-CD 20)
- 7.4.2 CP-690550
- 7.4.3 Ocrelizumab (R1594)
- 7.5 Selected Phase II Products in Development
- 7.5.1 Eculizumab
- 7.5.2 INCB018424
- 7.5.3 ALD-518
- 7.5.4 P38 MAP Kinase Inhibitor
- 7.5.5 BMS 561392
- 7.5.6 Lymphostat-B
- 7.5.7 VX 702
8 THE FINANCIAL OUTLOOK FOR THE RA THERAPY MARKET
- 8.1 Financial Forecasts for Key Products
- 8.1.1 Enbrel
- 8.1.2 Remicade
- 8.1.3 Humira
- 8.1.4 Orencia
- 8.1.5 Rituxan
- 8.2 Overall Financial Forecast for RA Market 2009-2013
GRAPHS
- Graph 3.1 Prevalence of RA in Various Countries
- Graph 6.1 Global Sales of Leading RA Therapies 2003-2008, by product ($ mn)
- Graph 6.2 US Sales of Leading RA Therapies 2003-2008, by product ($ mn)
- Graph 6.3 Non-US Sales of Leading RA Therapies 2003-2008, by product ($ mn)
- Graph 6.4 Enbrel Market Share, by Country/Region 2008
- Graph 6.5 Remicade Market Share, by Country/Region 2008
- Graph 6.6 Humira Market Share, by Country/Region 2008
- Graph 6.7 Orencia Market Share, by Country/Region 2008
- Graph 6.8 Global Market Share of Leading RA Therapies by Product, 2008
- Graph 6.9 US Market Share of Leading RA Therapies by Product, 2008
- Graph 6.10 Non-US Market Share of Leading RA Therapies by Product, 2008
- Graph 6.11 RA Therapy Market Share, by Country/Region 2008
- Graph 8.1 Sales Forecast for Enbrel 2009-2013
- Graph 8.2 Sales Forecast for Remicade 2009-2013
- Graph 8.3 Sales Forecast for Humira 2009-2013
- Graph 8.4 Sales Forecast for Orencia 2009-2013
- Graph 8.5 Sales Forecast for Rituxan 2009-2013
FIGURES
- Figure 4.1 Treatment Options for Rheumatoid Arthritis
TABLES
- Table 4.1 Percent of Patients with ACR Responses in Studies 1 and 3
- Table 5.1 Approved DMARDs for Rheumatoid Arthritis
- Table 5.2 Profiles of the Leading DMARDs and BRMs (2008)
- Table 6.1 Global Sales of Key BRMs for Rheumatoid Arthritis, 2003-2008 ($
million)
- Table 6.2 US Sales of Leading RA Therapies 2003-2008 ($ mn)
- Table 6.3 Non-US Sales of Leading RA Therapies 2003-2008 ($ mn)
- Table 6.4 Global Sales of Enbrel, US & Canada, Rest of World 2003-2008 ($
mn)
- Table 6.5 Sales of Remicade 2003-2008, US, Japan, Europe + Rest of World
($ mn)
- Table 6.6 Global Sales of Humira, US, Rest of World 2003-2008 ($ mn)
- Table 6.7 Global Sales of Orencia, US, Rest of World 2006-2008 ($ mn)
- Table 7.1 Rheumatoid Arthritis Drugs in Late-Stage Development
- Table 7.2 Rheumatoid Arthritis Drugs in Early-Stage Development
- Table 8.1 Patent Expirations for Key RA Products
- Table 8.2 Financial Growth Forecast of the Biologics in the RA Market
2009-2013 ($ mn)
|
